4 Results for "

IL 1 Trap

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "IL 1 Trap" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-P99444
CAS No.: 2173054-79-8
Synonyms: MSTT 1041A; RG 6149
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .
loading...
    loading...
Cat. No.: HY-108822
CAS No.: 501081-76-1
Purity:  ≥95.0%
Synonyms: Arcalyst; IL 1 Trap; Interleukin 1 Trap

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes .
loading...
    loading...
Cat. No.: HY-W996116
CAS No.: 1933460-23-1
AZM198 is an orally active myeloperoxidase (MPO) inhibitor. AZM198 irreversibly inactivates MPO (IC50=0.015 μM) via covalent binding to the heme prosthetic group, preferentially targets extracellular MPO activity, and reduces neutrophil extracellular trap formation, reactive oxygen species production and degranulation. AZM198 increases the fibrous cap thickness of atherosclerotic plaques, reduces lesion area, ameliorates hepatic steatosis and fibrosis in non-alcoholic steatohepatitis, and alleviates proteinuria and inflammatory infiltration associated with glomerulonephritis. AZM198 also decreases circulating levels of high-sensitivity Cardiac Troponin I and IL-1β, and mitigates endothelial cell injury. Therefore, AZM198 is suitable for research on various MPO-related diseases, including atherosclerotic cardiovascular disease, myocardial infarction, ischemic stroke, non-alcoholic steatohepatitis and crescentic glomerulonephritis .
loading...
    loading...
Cat. No.: HY-168002
CAS No.: 62578-87-4
Research Areas:  

Inflammation/Immunology

MPO-IN-8 is an orally active myeloperoxidase (MPO) inhibitor. MPO-IN-8 can inhibit the generation of hypochlorous acid in neutrophils and the release of extracellular traps (NETosis). In mice with gouty arthritis, MPO-IN-8 can reduce swelling, lower peroxidase activity, and decrease IL-1β levels .
loading...
    loading...